Indian drugmaker Strides Pharma Science said on Friday its unit Stelis Biopharma has partnered with Russia's sovereign fund to make at least 200 million doses of the Sputnik V Covid-19 vaccine, bringing India's total production of the shot to over half a billion doses.
Stelis' pact with the Russian Direct Investment Fund (RDIF) follows similar deals struck by Indian pharmaceutical firms Gland Pharma and Hetero to make millions of doses of the vaccine, which has proven to be 91.6 per cent effective against Covid-19.
India has now become one of the biggest producers of Sputnik V outside of Russia. Other